Oxana Crysler

1.1k total citations · 1 hit paper
25 papers, 432 citations indexed

About

Oxana Crysler is a scholar working on Oncology, Surgery and Hepatology. According to data from OpenAlex, Oxana Crysler has authored 25 papers receiving a total of 432 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 9 papers in Surgery and 6 papers in Hepatology. Recurrent topics in Oxana Crysler's work include Colorectal Cancer Treatments and Studies (8 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers) and Hepatocellular Carcinoma Treatment and Prognosis (6 papers). Oxana Crysler is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers) and Hepatocellular Carcinoma Treatment and Prognosis (6 papers). Oxana Crysler collaborates with scholars based in United States, Spain and Japan. Oxana Crysler's co-authors include Bruno Sangro, Bassel F. El‐Rayes, Ignacio Melero, Yoshito Itoh, Kazushi Numata, Ryoko Kuromatsu, Armando Santoro, Francesco Di Costanzo, Jaclyn Neely and Yun Shen and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Journal of Hepatology.

In The Last Decade

Oxana Crysler

22 papers receiving 427 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis

2021 141 citations Masatoshi Kudo, Ana Matilla et al. Journal of Hepatology profile →

Peers

Countries citing papers authored by Oxana Crysler

Since Specialization

Citations

This map shows the geographic impact of Oxana Crysler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oxana Crysler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oxana Crysler more than expected).

Fields of papers citing papers by Oxana Crysler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oxana Crysler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oxana Crysler. The network helps show where Oxana Crysler may publish in the future.

Co-authorship network of co-authors of Oxana Crysler

This figure shows the co-authorship network connecting the top 25 collaborators of Oxana Crysler. A scholar is included among the top collaborators of Oxana Crysler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oxana Crysler. Oxana Crysler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety outcomes with tremelimumab (T) rechallenge in the phase 3 HIMALAYA study of T plus durvalumab (D) in unresectable hepatocellular carcinoma. 2026 ·Journal of Clinical Oncology ·Robin Kate Kelley, Stephen L. Chan, J. Furuse, (unknown), (unknown), (unknown), Oxana Crysler, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Mark Yarchoan, (unknown), Vicky Tsipouri, (unknown), (unknown)	0
2	Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, CHS-388) in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC). 2025 ·Journal of Clinical Oncology ·Daneng Li, Kun‐Ming Rau, Ming‐Lung Yu, Hong Jae Chon, Meredith Pelster, Stuart K. Roberts, Oxana Crysler, Gina M. Vaccaro, Hyung‐Don Kim, Koho Iizuka, Hong Tang, Varun N. Kapoor, Daniel J. Chin, (unknown), Yoon‐Koo Kang	1
3	Perioperative versus adjuvant therapy in resectable pancreas cancer. 2025 ·Journal of Clinical Oncology ·Tianyi Wang, (unknown), (unknown), Brian D. Griffith, Valerie Gunchick, Thomas Enzler, Oxana Crysler, Kyle C. Cuneo, Hari Nathan, Theodore S. Lawrence, Mark M. Zalupski, Clifford S. Cho, Vaibhav Sahai, Filip Bednar	0
4	127O Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) 2024 ·Annals of Oncology ·Mitsuhiro Kudo, Lorenza Rimassa, (unknown), Bruno Sangro, George Lau, В. В. Бредер, (unknown), Oxana Crysler, (unknown), Tu Van Dao, Adilson Faccio, Junji Furuse, L-B. Jeng, Y-K. Kang, Robin Kate Kelley, Michael J. Paskow, (unknown), Di Ran, Alejandra Negro, (unknown)	1
5	Treatment of Locally Recurrent Rectal Cancer 2024 ·The Cancer Journal ·(unknown), Samantha Hendren, John C. Krauss, Oxana Crysler, Kyle C. Cuneo	0
6	Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04). 2024 ·Journal of Clinical Oncology ·Vaibhav Sahai, Kent A. Griffith, David B. Zhen, Dustin A. Deming, Rachna T. Shroff, David Hsieh, Devalingam Mahalingam, Oxana Crysler, Angela Alistar, David L. Bajor, Thomas Enzler, Mark M. Zalupski	2
7	First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors 2024 ·Cancer Research Communications ·Mark Yarchoan, John D. Powderly, Bruno R. Bastos, Thomas B. Karasic, Oxana Crysler, Pamela N. Münster, Meredith McKean, Leisha A. Emens, Yvonne M. Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C. Whiting, (unknown), Peppi Prasit, (unknown), Nathan Standifer, Thomas W. Dubensky, Sam H. Whiting, Susanna V. Ulahannan	11
8	Management and mechanism of calciphylaxis in a patient treated with the FGFR inhibitor pemigatinib—a case report 2024 ·Journal of Gastrointestinal Oncology ·Sreenivasa R Chandana, (unknown), (unknown), (unknown), Oxana Crysler, (unknown), (unknown)	2
9	BilT03: Phase 1b/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer 2024 ·Med ·Vaibhav Sahai, Kent A. Griffith, Bruce Lin, Heloisa P. Soares, Sreenivasa R Chandana, Oxana Crysler, Chandan Kumar‐Sinha, Thomas Enzler, (unknown), Valerie Gunchick, Mark M. Zalupski	2
10	PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma 2024 ·The Oncologist ·(unknown), (unknown), Valerie Gunchick, (unknown), Chandan Kumar‐Sinha, Oxana Crysler, Mark M. Zalupski, Vaibhav Sahai	3
11	947MO Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) 2024 ·Annals of Oncology ·Lorenza Rimassa, (unknown), Bruno Sangro, George Lau, (unknown), В. В. Бредер, (unknown), Oxana Crysler, (unknown), Tu Van Dao, Adilson Faccio, Junji Furuse, L-B. Jeng, Y-K. Kang, (unknown), Michael J. Paskow, (unknown), Di Ran, (unknown), (unknown)	9
12	Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04) 2023 ·Clinical Cancer Research ·(unknown), Kent A. Griffith, (unknown), David B. Zhen, Chandan Kumar‐Sinha, Oxana Crysler, David Hsiehchen, Thomas Enzler, (unknown), Valerie Gunchick, Abhinav Achreja, Olamide Animasahun, (unknown), (unknown), Arul M. Chinnaiyan, Deepak Nagrath, Mark M. Zalupski, Vaibhav Sahai	18
13	Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository 2023 ·Clinical Pharmacology & Therapeutics ·Amy L. Pasternak, (unknown), (unknown), (unknown), Oxana Crysler, Paul Swiecicki, Bryan J. Schneider, Brett Vanderwerff, N. Lynn Henry, John C. Krauss, Vaibhav Sahai, Daniel L. Hertz	1
14	Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. 2023 ·Journal of Clinical Oncology ·Deepti Behl, Michael Rothe, Pam K. Mangat, Elizabeth Garrett‐Mayer, (unknown), Oxana Crysler, Elie G. Dib, (unknown), Michael J. Hall, (unknown), Olatunji B. Alese, Alissa Marr, (unknown), (unknown), Ramya Thota, Eddy S. Yang, (unknown), (unknown), Susan Halabi, Richard L. Schilsky	5
15	Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02. 2023 ·Journal of Clinical Oncology ·Vaibhav Sahai, Kent A. Griffith, Laura W. Goff, Oxana Crysler, Thomas Enzler, Mark M. Zalupski	3
16	Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC). 2023 ·Journal of Clinical Oncology ·Oxana Crysler, Mark Yarchoan, Junji Furuse, Peter R. Galle, Wattana Sukeepaisarnjaroen, Nguyễn Tiến Thịnh, Gianluca Masi, Ho Yeong Lim, Marı́a Varela, Charu Gupta, (unknown), Alejandra Negro, Ghassan K. Abou‐Alfa	2
17	A multicenter phase Ib/II study of liposomal-irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) with nivolumab as second-line therapy for patients with advanced biliary tract cancer (BilT-03). 2022 ·Journal of Clinical Oncology ·Vaibhav Sahai, Kent A. Griffith, Bruce Lin, Heloisa P. Soares, Sreenivasa R Chandana, Oxana Crysler, Thomas Enzler, Mark M. Zalupski	2
18	A phase 1 study of TPST-1120 as a single agent and in combination with nivolumab in subjects with advanced solid tumors. 2022 ·Journal of Clinical Oncology ·Mark Yarchoan, John D. Powderly, Bruno R. Bastos, Thomas B. Karasic, Oxana Crysler, Pamela N. Münster, Meredith McKean, Leisha A. Emens, Yvonne M. Saenger, Yasser Ged, (unknown), Andreas Goutopoulos, (unknown), (unknown), Peppi Prasit, Thomas W. Dubensky, Sam H. Whiting, Susanna V. Ulahannan	5
19	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis breakdown → 2021 ·Journal of Hepatology ·Masatoshi Kudo, Ana Matilla, Armando Santoro, Ignacio Melero, Antonio Cubillo Gracián, Mirelis Acosta-Rivera, Su Pin Choo, Anthony B. El-Khoueiry, Ryoko Kuromatsu, Bassel F. El‐Rayes, Kazushi Numata, Yoshito Itoh, Francesco Di Costanzo, Oxana Crysler, María Reig, Yun Shen, Jaclyn Neely, Marina Tschaika, Tami Wisniewski, Bruno Sangro	141
20	Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. 2019 ·Journal of Clinical Oncology ·Masatoshi Kudo, Ana Matilla, Armando Santoro, Ignacio Melero, Antonio Cubillo Gracián, Mirelis Acosta-Rivera, Su Pin Choo, Anthony B. El-Khoueiry, Ryoko Kuromatsu, Bassel F. El‐Rayes, Kazushi Numata, Yoshito Itoh, Francesco Di Costanzo, Oxana Crysler, María Reig, Yun Shen, Jaclyn Neely, Christine Marie Dela Cruz, (unknown), Bruno Sangro	79

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact